In addition, clinical trials with broad spectrum inhibitors sorafenib and pazopanib, that both also target VEGFR-3, have shown improved progression-free survival rates in adult angio-, leimomyo- and synovial sarcomas [38], [39]. This evidence concerns the gene FLT4 and synovial sarcoma.